Recombinant Human PCSK9 protein, Strep-tagged

• Cat.No.: PCSK9-351H
• Product Overview: Recombinant Human PCSK9 protein (Gln31-Gln692), fused to Strep tag at C-terminus, was expressed in human 293 cells (HEK293).

Specification

• Description: Proprotein convertase subtilisin/kexin type 9 (PCSK9), is an enzyme which in humans is encoded by the PCSK9 gene. This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. This protein plays a major regulatory role in cholesterol homeostasis. PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. PCSK9 may also have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a rare form of autosomal dominant familial hypercholesterolemia (HCHOLA3).
• Source: HEK293
• Species: Human
• Tag: Strep
• Form: Lyophilized from 0.22 um filtered solution in PBS, pH7.4, 10% trehalose.
• Molecular Mass: The protein has a calculated MW of 73.5 kDa. The protein migrates as 17 kDa and 62-67 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation and proteolytic digestion.
• Protein length: 662
• Endotoxin: Less than 1.0 EU per ug by the LAL method.
• Purity: >97% as determined by SDS-PAGE.
• Storage: For long term storage, the product should be stored at lyophilized state at -20 centigrade or lower.
  Please avoid repeated freeze-thaw cycles.
  This product is stable after storage at:
  -20 centigrade to -70 centigrade for 12 months in lyophilized state;
  -70 centigrade for 3 months under sterile conditions after reconstitution.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents.

Gene Information

• Gene Name: PCSK9
• Official Symbol: PCSK9
• Synonyms: PCSK9; proprotein convertase subtilisin/kexin type 9; HCHOLA3, hypercholesterolemia, autosomal dominant 3; FH3; NARC 1; NARC1; NARC-1; HCHOLA3
• Gene ID: 255738
• mRNA Refseq: NM_174936.4
• Protein Refseq: NP_777596.2
• MIM: 607786
• UniProt ID: Q8NBP7

Reviews

11/13/2022

In immunological experiments, it was found that it had good antigenicity and could induce target immune responses.

07/07/2022

It promoted cell growth and proliferation.

03/04/2022

High catalytic efficiency.

Q&As

Is there a relationship between genetic mutations in the PCSK9 protein and cardiovascular disease?

Yes, some studies suggest that mutations in the PCSK9 protein gene may increase the risk of cardiovascular disease. For example, some PCSK9 mutations can cause their dysfunction, resulting in hypercholesterolemia and cardiovascular disease.

How can PCSK9 protein be used for vaccine development?

PCSK9 protein is combined with immune adjuvants to make a vaccine, or mutated PCSK9 protein to induce an immune response to it, inhibit PCSK9 expression in vivo, increase LDLR levels and reduce serum cholesterol levels.

What is the relationship between PCSK9 protein and obesity?

This protein may have a regulatory effect on weight and obesity, and it is associated with glucose and endocannabinin homeostasis studies have linked PCSK9 to the development of obesity and diabetes.

What are the new prospects for future therapies that inhibit PCSK9 protein?

Several new anti-PCSK9 drugs are already being studied and developed, including oral drugs and gene chromosome therapies, and some drugs have advanced to early stages of clinical trials, providing new options for the treatment of PCSK9 proteins.

What drugs are currently available to inhibit the PCSK9 protein?

Currently on the market to inhibit PCSK9 protein drugs include alirocumab and evolocumab.

What is the relationship between PCSK9 protein and hypercholesterolemia?

PCSK9 protein can degrade LDLR protein, so its overexpression will lead to a decrease in LDLR's ability to be cleared, leading to hypercholesterolemia.